Demyelination is the pathological process of losing or destroying the myelin sheath that surrounds neuronal axons, leading to impaired nerve conduction and neurological dysfunction[@compston2002]. This process is a hallmark feature of [multiple sclerosis](/diseases/multiple-sclerosis) (MS) and other demyelinating diseases, but also occurs secondary to [neurodegenerative processes](/mechanisms/neurodegeneration-pathways) in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and vascular dementia[@bartzokis2004]. The myelin sheath, produced by [oligodendrocytes](/cell-types/oligodendrocytes) in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS), provides essential electrical insulation that enables rapid saltatory conduction of action potentials along axons[@nave2014].
The mechanisms underlying demyelination are complex and multifactorial, involving [immune-mediated](/mechanisms/neuroinflammation-ad) destruction, [metabolic dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration), [oxidative stress](/mechanisms/oxidative-stress-neurodegeneration), and genetic predisposition. Understanding these mechanisms is critical for developing therapeutic strategies to promote remyelination and preserve neurological function.
Demyelination is the pathological process of losing or destroying the myelin sheath that surrounds neuronal axons, leading to impaired nerve conduction and neurological dysfunction[@compston2002]. This process is a hallmark feature of [multiple sclerosis](/diseases/multiple-sclerosis) (MS) and other demyelinating diseases, but also occurs secondary to [neurodegenerative processes](/mechanisms/neurodegeneration-pathways) in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and vascular dementia[@bartzokis2004]. The myelin sheath, produced by [oligodendrocytes](/cell-types/oligodendrocytes) in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS), provides essential electrical insulation that enables rapid saltatory conduction of action potentials along axons[@nave2014].
The mechanisms underlying demyelination are complex and multifactorial, involving [immune-mediated](/mechanisms/neuroinflammation-ad) destruction, [metabolic dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration), [oxidative stress](/mechanisms/oxidative-stress-neurodegeneration), and genetic predisposition. Understanding these mechanisms is critical for developing therapeutic strategies to promote remyelination and preserve neurological function.
The immune system plays a central role in demyelination through both cell-mediated and humoral mechanisms. In [multiple sclerosis](/diseases/multiple-sclerosis), autoreactive T lymphocytes recognizing myelin antigens cross the [blood-brain barrier](/entities/blood-brain-barrier) and initiate an inflammatory cascade that leads to [oligodendrocyte](/cell-types/oligodendrocytes) death and myelin destruction[@dendrou2015]. CD4+ T helper cells, particularly Th1 and Th17 subsets, release pro-inflammatory cytokines including interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-17 (IL-17) that activate [microglia](/cell-types/microglia) and [astrocytes](/cell-types/astrocytes) and recruit additional immune cells to the CNS[@korn2009].
B cells and plasma cells produce autoantibodies against myelin proteins such as myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG). These antibodies can mediate demyelination through complement activation and antibody-dependent cellular cytotoxicity[@weber2010]. The presence of oligoclonal bands in the cerebrospinal fluid of MS patients reflects intrathecal immunoglobulin synthesis and B cell involvement in the disease process[@frederiksen2019].
[Oligodendrocytes](/cell-types/oligodendrocytes), the myelin-producing cells of the CNS, undergo [apoptosis](/mechanisms/apoptosis-neurodegeneration) or [necroptosis](/mechanisms/necroptosis-pathway-neurodegeneration) in response to various toxic stimuli during demyelination. [Excitotoxicity](/mechanisms/excitotoxicity-neurodegeneration) mediated by excessive glutamate release from activated microglia and astrocytes damages oligodendrocytes through AMPA and NMDA receptor activation[@pitt2000]. The glutamate transporter EAAT2 (also known as GLT-1) is downregulated in demyelinating lesions, leading to extracellular glutamate accumulation and oligodendrocyte toxicity[@vanhoutte2006].
[Oxidative stress](/mechanisms/oxidative-stress-neurodegeneration) contributes significantly to oligodendrocyte death in demyelinating diseases. Oligodendrocytes have low levels of antioxidant defenses compared to neurons, making them particularly vulnerable to reactive oxygen species (ROS) generated by inflammatory cells[@van2011]. [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) in oligodendrocytes leads to ATP depletion, [calcium dysregulation](/mechanisms/calcium-homeostasis-neurodegeneration), and activation of apoptotic pathways[@mahad2015].
TNF-α directly induces oligodendrocyte apoptosis through TNF receptor 1 (TNFR1) signaling, activating caspase-3 and the intrinsic mitochondrial apoptosis pathway[@akassoglou1998]. Additionally, TNF-α can trigger necroptosis—a programmed form of necrotic cell death—in oligodendrocytes lacking functional caspase-8, leading to release of intracellular contents and amplified inflammation[@ofengeim2015].
[Autophagy](/mechanisms/autophagy-mechanisms), the cellular process responsible for degrading damaged organelles and protein aggregates, plays a dual role in demyelination. While basal autophagy protects oligodendrocytes from stress, dysregulated autophagy can contribute to myelin breakdown[@liu2016]. The mTOR signaling pathway, a key regulator of autophagy, is hyperactive in demyelinating lesions, inhibiting autophagic flux and promoting oligodendrocyte death[@miron2021].
LC3-associated phagocytosis (LAP) is involved in the clearance of myelin debris by microglia and macrophages. Defects in LAP impair debris clearance and create a pro-inflammatory environment that inhibits remyelination[@martinez2015]. The transcription factor TFEB (Transcription Factor EB) controls expression of autophagy and lysosomal genes; its nuclear translocation is reduced in oligodendrocytes from MS patients, compromising cellular clearance mechanisms[@wang2012].
Multiple sclerosis is the most common demyelinating disease of the CNS, affecting approximately 2.8 million people worldwide[@walton2020]. MS is characterized by focal demyelinated plaques in the white matter, cortex, and spinal cord, with associated neuroaxonal loss and gliosis. The disease follows a relapsing-remitting course in approximately 85% of patients, with periods of neurological dysfunction followed by partial or complete recovery[@lublin2013].
Pathologically, MS lesions demonstrate inflammatory infiltrates consisting of T lymphocytes, B cells, and macrophages, along with complement deposition and active myelin degradation[@lucchinetti2000]. Chronic lesions show demyelinated axons surrounded by astrocytic gliosis (scar tissue). The progressive forms of MS (primary progressive and secondary progressive) are characterized by more diffuse neurodegeneration and cortical pathology[@lassmann2021].
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disease primarily targeting the optic nerves and spinal cord. Unlike MS, NMOSD is associated with autoantibodies against aquaporin-4 (AQP4), a water channel expressed on astrocytes[@lennon2004]. These antibodies mediate complement-dependent cytotoxicity, leading to astrocyte loss and secondary demyelination. NMOSD lesions are characterized by perivascular immunoglobulin and complement deposition, with necrotic cavitation in severe cases[@lucchinetti2014].
Acute disseminated encephalomyelitis (ADEM) is a monophasic demyelinating syndrome typically following infections or vaccinations. It presents with multifocal CNS lesions and diffuse neurological symptoms including encephalopathy, motor deficits, and sensory disturbances[@tenembaum2002]. Pathologically, ADEM shows perivenular inflammation and demyelination, with a pattern reminiscent of experimental autoimmune encephalomyelitis (EAE) in animal models[@wingerchuk2003].
Guillain-Barré syndrome (GBS) represents the most common cause of acute demyelination in the peripheral nervous system. This autoimmune disorder targets peripheral nerve myelin, leading to progressive weakness, areflexia, and sensory disturbances[@willison2016]. Molecular mimicry between microbial antigens (particularly from Campylobacter jejuni) and peripheral nerve gangliosides triggers the production of autoantibodies that cross-react with myelin antigens[@yuki2012].
While Alzheimer's disease (AD) is primarily characterized by amyloid-beta plaques and tau neurofibrillary tangles, demyelination occurs as a secondary process that contributes to cognitive decline[@bartzokis2011]. White matter lesions are frequently observed in AD patients on MRI, reflecting both demyelination and axonal loss[@yoshita2013]. Oligodendrocyte dysfunction and death in AD may result from amyloid-beta toxicity, tau pathology spreading to oligodendrocytes, and impaired neurotrophic support[@desai2022].
The myelin degradation products released during demyelination can promote amyloid-beta aggregation and spread, creating a vicious cycle between demyelination and amyloid pathology[@van2016]. Furthermore, demyelination disrupts saltatory conduction and leads to calcium dysregulation in demyelinated axons, contributing to synaptic dysfunction and cognitive decline[@cai2020].
Parkinson's disease (PD) involves demyelination in both the central and peripheral nervous systems. Alpha-synuclein pathology spreads through white matter tracts, and oligodendrocytes can accumulate Lewy bodies, leading to their dysfunction and death[@halliday2022]. White matter hyperintensities on MRI correlate with disease severity and cognitive impairment in PD patients[@beyer2006].
Peripheral demyelination contributes to autonomic dysfunction in PD through damage to autonomic nerve fibers. Additionally, demyelination of dopaminergic pathways may impair signal transmission and contribute to motor fluctuations[@jellinger2023].
Vascular dementia (VaD) results from cerebrovascular disease-related injury to white matter, where demyelination occurs secondary to chronic hypoperfusion and small vessel disease[@iadecola2013]. White matter lesions in VaD show diffuse demyelination, axonal loss, and gliosis, with impaired oligodendrocyte maturation and repair capacity[@shimada2020]. The vascular risk factors that cause VaD—including hypertension, diabetes, and atherosclerosis—also promote endothelial dysfunction and blood-brain barrier breakdown, facilitating immune cell infiltration and demyelination[@wardlaw2013].
Following demyelination, endogenous oligodendrocyte progenitor cells (OPCs) proliferate, migrate to lesional borders, and differentiate into mature oligodendrocytes that regenerate myelin sheaths[@franklin2008]. This process, called remyelination, restores nerve conduction and provides protection to denuded axons. However, remyelination often fails or is incomplete in chronic demyelinating diseases, leading to persistent neurological deficits[@goldschmidt2009].
OPCs express the NG2 proteoglycan and PDGFRα, and can be identified by their distinctive morphology and response to growth factors. The differentiation of OPCs into mature oligodendrocytes is regulated by transcription factors including Olig2, Sox10, and Nkx2.2[@rowitch2019]. Signaling through the Notch1, Wnt, and BMP pathways must be precisely balanced to enable efficient differentiation; dysregulation of these pathways contributes to remyelination failure[@fancy2011].
Multiple factors limit successful remyelination in demyelinating diseases. The inflammatory environment in chronic lesions—characterized by high levels of TNF-α, IFN-γ, and Notch ligands—inhibits OPC differentiation[@zhang2021]. Astrocytes in chronic lesions produce chondroitin sulfate proteoglycans (CSPGs) that impede OPC migration and process extension through the lesion core[@lau2013].
Axonal degeneration removes the synaptic and axonal signals that promote oligodendrocyte survival and differentiation. Demyelinated axons may lose the capacity to support remyelination due to ion channel redistribution and metabolic compromise[@trapp2009]. Additionally, OPCs themselves may undergo senescence or adopt a reactive phenotype that impairs their regenerative capacity[@nicchia2022].
Disease-modifying therapies for MS target various steps in the immune-mediated demyelination cascade. Interferon-beta and glatiramer acetate shift the immune response toward anti-inflammatory Th2 phenotypes[@dhibjalbut2003]. Natalizumab and fingolimod block immune cell trafficking into the CNS[@cohen2010]. Alemtuzumab depletes circulating T and B lymphocytes, while ocrelizumab targets CD20+ B cells[@hauser2017].
These therapies effectively reduce relapse rates and slow disease progression but do not directly promote remyelination. Moreover, some immunomodulatory agents may impair endogenous repair mechanisms by reducing the beneficial inflammatory signals that support remyelination[@ruck2014].
Pharmacological promotion of remyelination represents a major therapeutic frontier. The monoclonal antibody Lingo-1 antagonist (opicinumab) blocks the Lingo-1 receptor on OPCs, promoting their differentiation and remyelination in preclinical models[@mi2005]. However, clinical trials showed limited efficacy in MS patients[@cadavid2017].
Small molecules including clemastine, benztropine, and miconazole have been identified in drug screens as promyelinating agents and are being evaluated in clinical trials[@mei2014]. These drugs appear to work through inhibition of muscarinic signaling or activation of oligodendrocyte differentiation pathways[@deshmukh2013].
Cell transplantation approaches aim to replace lost oligodendrocytes and restore myelin. Mesenchymal stem cells (MSCs), neural stem cells (NSCs), and OPCs have been tested in preclinical models and early clinical trials[@pluchino2003]. These cells can promote remyelination through both direct differentiation into oligodendrocytes and paracrine secretion of trophic factors[@uccelli2008].
Induced pluripotent stem cell (iPSC)-derived OPCs represent a promising approach for personalized cell therapy. Patient-derived iPSCs can be differentiated into OPCs and transplanted into demyelinated lesions, potentially providing a renewable source of myelin-forming cells[@wang2013]. Challenges remain regarding cell survival, appropriate migration, and functional integration within the host nervous system.
Experimental autoimmune encephalomyelitis (EAE) is the most widely used animal model for studying demyelination and testing therapeutic interventions. EAE is induced by immunization with myelin proteins (MBP, PLP, MOG) or peptides, leading to autoimmune T cell-mediated demyelination that recapitulates key features of MS[@baxter2007]. Different immunization protocols produce distinct disease courses, allowing study of acute, chronic, or relapsing-remitting demyelination[@constantinescu2012].
The EAE model has been instrumental in understanding immune pathogenesis and developing disease-modifying therapies. However, important differences between EAE and MS—including the predominant role of humoral immunity in some models and the absence of cortical lesions in typical EAE—limit its translational value[@sriram2005].
Chemical toxins including ethidium bromide, lysolecithin, and cuprizone induce focal demyelination without primary immune involvement, enabling study of demyelination and remyelination in isolation[@blakemore2000]. The cuprizone model produces reversible demyelination in the corpus callosum through copper chelation and oligodendrocyte toxicity, making it particularly useful for studying remyelination[@armstrong2002].
These toxin models complement EAE by providing insights into non-immune-mediated demyelination and the endogenous repair response. They are especially valuable for screening remyelination-promoting drugs and understanding the cellular and molecular mechanisms of oligodendrocyte death and regeneration[@hiremath1998].
Demyelination represents a common final pathway in numerous neurological disorders, with immune-mediated, degenerative, and vascular etiologies converging on loss of the insulating myelin sheath. The molecular mechanisms underlying demyelination involve complex interactions between immune cells, oligodendrocytes, astrocytes, and axons. Understanding these mechanisms is essential for developing therapies that not only suppress inflammatory demyelination but also promote remyelination and functional recovery.
While significant progress has been made in treating relapsing forms of MS, the challenge of promoting remyelination in chronic demyelinating diseases remains unmet. Future therapeutic strategies will likely combine immunomodulation with remyelination-promoting approaches, potentially incorporating cell-based therapies for patients with inadequate endogenous repair capacity.
The following diagram shows the key molecular relationships involving Demyelination discovered through SciDEX knowledge graph analysis: